The Pharma Navigator

CDMO, Suven Pharmaceuticals, aims to reach USD 1 bn in revenue by 2030, by investing in new facilities to increase production capacity and strengthen its capabilities in drug development and manufacturing to support global pharmaceutical clients. Focusing on specialized molecules and complex drug formulations, Suven plans to capitalize on growing demand in the CDMO sector through strategic partnerships, innovation, and operational efficiency to become a major player in the global pharmaceutical manufacturing market. Read more here👇

Advanced therapy medicinal products specialist CDMO, Porton Advanced | ATMP CDMO/CRO, and clinical-stage biotech, Eureka Therapeutics, Inc, have entered a strategic collaboration to accelerate the development and commercialization of T-cell therapies for cancer treatment. The partnership leverages Porton Advanced’s expertise in cell and gene therapy development and manufacturing with Eureka’s proprietary ARTEMIS T-cell receptor platform, designed to enhance the precision and efficacy of T-cell therapies. The collaboration aims to streamline the development process, reduce costs, and bring innovative cancer treatments to market faster. By leveraging their combined capabilities, both companies seek to deliver scalable, high-quality cell therapies. Read more here👇

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗖𝗼𝗺𝗽𝗹𝗲𝘅 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀: 𝗢𝘃𝗲𝗿𝗰𝗼𝗺𝗶𝗻𝗴 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗳𝗿𝗼𝗺 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘁𝗼 𝗖𝗹𝗶𝗻𝗶𝗰.   Gain insights into novel approaches for cell line development, analytics for complex biologics, and AI-driven solutions that streamline the path from discovery to launch.   In case you missed the Fierce Advanced Biologics virtual event, please view the on demand sessions here 👉 https://lnkd.in/eTQAWaPh

Biologics CDMO, Wheeler Bio, Inc., has successfully raised USD 35 mn in an oversubscribed Series A-1 funding round. The funds will help the company strengthen its biologics’ manufacturing capabilities, such as planning the development of a large-scale facility, and enhance the manufacturing facility by expanding its services and advance its cutting-edge technologies in biologic production. Read more here👇

Canadian CDMO, Delpharm, has secured a USD 42 mn investment from the Canadian Government to enhance the production capacity of its injectables manufacturing facility in Montreal, Canada. The facility upgrade will improve efficiency, regulatory compliance, and the ability to handle complex injectable formulations, ensuring Delpharm’s continued growth in the competitive CDMO sector. Furthermore, through the investment, the company will be able to support its pharmaceutical clients with advanced drug manufacturing and injectables solutions. Read more here👇

Curium Pharma, a global leader in nuclear medicine, has announced the acquisition of radiopharmaceutical company, Eczacıbaşı-Monrol Nuclear Products, as the company aims to improve its position in the global nuclear medicine market, particularly in the production of positron emission tomography (PET) radiopharmaceuticals. The acquisition expands Curium’s portfolio and strengthens its capabilities in providing innovative diagnostic solutions. With Monrol’s expertise in radiopharmaceutical manufacturing and strong presence in Europe, the acquisition will allow Curium to broaden its capabilities and better serve healthcare providers worldwide. Read more here👇

PharmaLogic is making moves to advance its strategy of becoming a fully-integrated service provider specialising in radiopharmaceutical therapies by acquiring a majority stake in Agilera Pharma AS. Under the terms of the agreement, PharmaLogic will commit to investment in Agilera's CDMO capabilities, strengthening its infrastructure, and scaling its manufacturing footprint to meet the growing demand for radiopharmaceutical therapeutics. Read more here 👇 https://lnkd.in/eDt5HJ9V

Novo Nordisk has entered into an exclusive global licensing agreement with Lexicon Pharmaceuticals, Inc. for Lexicon’s promising drug candidate, LX9851, which targets gastrointestinal disorders. LX9851 is a potent and selective inhibitor of Acyl-CoA Synthetase 5, which has a key role in regulating fat accumulation and energy balance, making the therapy potentially beneficial for patients with obesity and associated metabolic disorders. The arrangement grants Novo Nordisk worldwide rights to develop, manufacture, and commercialize LX9851, with Lexicon eligible for upfront, milestone, and royalty payments based on the drug’s success. The partnership also positions LX9851 for future clinical development and potential commercialization. Read more here👇

Spanish CDMO, Esteve Química, S.A., is investing USD 100 mn to expand its U.S. manufacturing capabilities, focusing on increasing production capacity for high potency APIs (HPAPIs) amid increasing market demands for their use. The expansion will strengthen the company’s U.S. presence and enable it to support pharmaceutical clients with state-of-the-art manufacturing services. Additionally, the expanded HPAPI capabilities will provide the company’s clients with access to advanced technologies and the expertise required to develop and manufacture life-saving therapies for oncology and other serious conditions. Read more here👇

Innovation, science, and pharmaceutical services partner, Bend Bioscience, is expanding its Gainesville, Georgia facility with the addition of a commercial-scale spray dryer and a Gerteis drug granulation system. With the increased capabilities, the company will be able to provide technologically advanced absorption- and bioavailability-enhanced products in addition to comprehensive clinical and commercial scale oral dose forms. The new spray drying suite will include a GEA PSD-4, adjacent secondary vacuum drying systems, multiple tank sizes for flexibility, and a dual-stage condenser. Additionally, the expanded facility will provide customers with the ability to process highly potent APIs. The new equipment is being shipped to the Georgia facility in April and the company expects to commence installation immediately. Read more here👇